Hemispherx BioPharma, Inc.
MarketLine (a Datamonitor Company)
20 Feb 2013
Available for Immediate Download
Hemispherx BioPharma, Inc. - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Hemispherx BioPharma, Inc. required for business and competitor intelligence needs - Intelligence on Hemispherx BioPharma, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Hemispherx BioPharma, Inc., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Hemispherx Biopharma (Hemispherx) is a pharmaceutical company engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The company’s products include Ampligen, Alferon N Injection and Alferon LDO (low dose oral). The company primarily operates in the US, where it is headquartered in Philadelphia, Pennsylvania and employs around 29 people. The company recorded revenues of $0.1 million in the fiscal year ended December 2010, an increase of 21.6% over 2009. The company's operating loss was $16.4 million in fiscal 2010, as compared to an operating loss of $13.3 million in 2009. Its net loss was $13.1 million in fiscal 2010, as compared to the net loss of $7.2 million in 2009. Reasons to Purchase: - Gain understanding of Hemispherx BioPharma, Inc. the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Hemispherx BioPharma, Inc. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Hemispherx BioPharma, Inc. your competitors' business structure, strategy and prospects